TY - JOUR T1 - Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer JF - Anticancer Research JO - Anticancer Res SP - 3643 LP - 3648 DO - 10.21873/anticanres.15154 VL - 41 IS - 7 AU - KOICHI OHATA AU - HIRONORI FUJII AU - SHIORI SADAKA AU - HIROKO KATO-HAYASHI AU - HIROTOSHI IIHARA AU - RYO KOBAYASHI AU - SHINYA UEMURA AU - TAKUJI IWASHITA AU - MASAHITO SHIMIZU AU - AKIO SUZUKI Y1 - 2021/07/01 UR - http://ar.iiarjournals.org/content/41/7/3643.abstract N2 - Background/Aim: To clarify the risk of chemotherapy-induced nausea and vomiting (CINV) with GnP therapy, gemcitabine (GEM) plus nab-paclitaxel (nab-PTX), we compared CINV between GEM and GnP therapy. Patients and Methods: Patients who had received an initial course of GEM and GnP therapy were enrolled. Primary endpoint was the incidence of nausea, and secondary endpoints were the incidence of vomiting and rescue. In addition, the association between nausea and combination therapy with GEM and nab-PTX was evaluated by multivariate logistic regression with adjustment for covariates. All patients received anti-cancer drugs under guideline-consistent, low-risk antiemetic measures. Results: Data from 105 patients were analyzed (GEM group, 44 patients; GnP group, 61 patients). The incidence of nausea, vomiting, and rescue did not significantly differ between the two groups during the acute, delayed or overall periods. The multivariate logistic regression analysis showed that combination therapy with GEM and nab-PTX was not significantly associated with nausea compared to GEM alone. Conclusion: Under guideline-consistent, low-risk antiemetic measures, GnP therapy-induced nausea and vomiting can be controlled similarly to when induced by GEM. ER -